FDA approves Phathom's VOQUEZNA for Erosive GERD; triggers $175M payment

Phathom Pharmaceuticals, Inc.

FDA approved VOQUEZNA (vonoprazan) for healing, maintenance, and heartburn relief in Erosive GERD.
Phase 3 PHALCON-EE trial showed 93% healing rate at Week 8 for VOQUEZNA 20mg vs 85% for lansoprazole.
VOQUEZNA demonstrated superiority in moderate-to-severe patients (70% vs 53% at Week 2).
Approval triggers a $175M non-dilutive payment from Revenue Interest Financing Agreement.
VOQUEZNA expected to launch in US in December 2023; marketed exclusively by Phathom.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.